Novel route of insulin delivery using an implant-mediated drug delivery system

Recent Advances in Hydrogels for the Diagnosis and Treatment of Dry Eye Disease

Dry eye disease (DED) is the most common clinical ocular surface disease. Given its multifactorial etiology, no consensus has been reached on the diagnosis criteria for dry eye disease. Topical drug administration remains the mainstay of treatment but is limited to the rapid clearance from the eye surface. To address these problems, hydrogel-based materials were designed to detect biomarkers or act as drug delivery systems by taking advantage of their good biocompatibility, excellent physical and mechanical properties, and long-term implant stability. Biosensors prepared using biocompatible hydrogels can be sensitive in diagnosing DED, and the designed hydrogels can also improve the drug bioavailability and retention time for more effective and long-term treatment. This review summarizes recent advances in the use of hydrogels for diagnosing and treating dry eye, aiming to provide a novel reference for the eventual clinical translation of hydrogels in the context of dry eye disease.

Biocompatible and Biomaterials Application in Drug Delivery System in Oral Cavity

Biomaterials applications have rapidly expanded into different fields of sciences. One of the important fields of using biomaterials is dentistry, which can facilitate implantation, surgery, and treatment of oral diseases such as peri-implantitis, periodontitis, and other dental problems. Drug delivery systems based on biocompatible materials play a vital role in the release of drugs into aim tissues of the oral cavity with minimum side effects. Therefore, scientists have studied various delivery systems to improve the efficacy and acceptability of therapeutic approaches in dental problems and oral diseases. Also, biomaterials could be utilized as carriers in biocompatible drug delivery systems. For instance, natural polymeric substances, such as gelatin, chitosan, calcium phosphate, alginate, and xanthan gum are used to prepare different forms of delivery systems. In addition, some alloys are conducted in drug complexes for the better in transportation. Delivery systems based on biomaterials are provided with different strategies, although individual biomaterial has advantages and disadvantages which have a significant influence on transportation of complex such as solubility in physiological environments or distribution in tissues. Biomaterials have antibacterial and anti-inflammatory effects and prolonged time contact and even enhance antibiotic activities in oral infections. Moreover, these biomaterials are commonly prepared in some forms such as particulate complex, fibers, microspheres, gels, hydrogels, and injectable systems. In this review, we examined the application of biocompatible materials in drug delivery systems of oral and dental diseases or problems.

Clinical and radiographic variables related to implants with simultaneous grafts among type 2 diabetic patients treated with different hypoglycemic medications: a retrospective study

Background

The influence of different hypoglycemic agents on peri-implant variables among type 2 diabetes mellitus patients is still unclear. Therefore, the aim of this study was to assess the radiographic marginal bone loss and clinical parameters around implants in patients using different hypoglycemic agents.

Methods

In this retrospective cohort study, the dental implant records of type 2 diabetes mellitus patients who met the inclusion criteria were collected. The patients using only single medication as follows: insulin, metformin, or glucagon-like peptide-1 (GLP-1) drugs, were grouped according to their medication. These patients received implant placement with the same initial status, and all the prosthesis restorations were cement-retained ceramic crowns. The peri-implant marginal bone levels were evaluated by periapical radiographs immediately after implant placement and at 1 and 2-year follow-up visits. The baseline characteristics were compared among groups. The peri-implant radiographic marginal bone loss and clinical parameters were preliminarily compared using the Kruskal–Wallis test, and then the covariates were controlled by covariance analysis. Bonferroni post hoc adjustment test was performed for the multiple comparisons.

Results

After a review of more than 7000 medical records, a total of 150 patients with 308 implants at 1-year follow-up were assessed. The peri-implant marginal bone loss in the GLP-1 drug group was significantly smaller than the insulin group and metformin group (P < 0.01). The radiographic bone loss in the metformin group was higher than the insulin group (P < 0.05). Some of these included patients were lost to follow-up. Only 74 patients with 129 implants completed the 2-year follow-up. The radiographic bone loss in the metformin group was still higher than the insulin group (P < 0.05) and GLP-1 group (P < 0.01). There was no significant difference in the BOP (+) and the mean PD among groups (P > 0.05).

Conclusions

The radiographic variables were not exactly the same among the patients with different hypoglycemic agents at both the 1 and 2-year follow-ups. After ensuring consistency in baseline characteristics, the positive effect of GLP-1 drugs on peri-implant bone remodeling may be no less than insulin or metformin. More studies are needed to verify the direct effect of these drugs on peri-implant bone.

Clinical trial registration number ChiCTR2000034211 (retrospectively registered).

Mussel adhesive protein blended with gelatin loaded into nanotube titanium dental implants enhances osseointegration

The purpose of this study was to investigate whether mussel adhesive protein (MAP) blended with gelatin loaded into nanotube titanium (Ti) dental implants enhances osseointegration and supports bone formation. Cell viability, crystal violet staining, Western blot analysis, alizarin red S staining, alkaline phosphatase (ALP) activity, micro-computed tomography (μ-CT), hematoxylin and eosin (H&E), and immunohistochemistry (IHC) staining were employed to test the biocompatibility of MAP blended with gelatin (MAP/Gel). MC3T3 E1 cells were used for in vitro and Sprague-Dawley rats for in vivo models in this study. MC3T3 E1 cells cultured in MAP/Gel loaded into nanotube Ti surface demonstrated activation of FAK-PI3K-MAPKs-Wnt/β-catenin signaling pathway and enhanced osteogenic differentiation. μ-CT, H&E, and IHC staining confirmed that MAP/Gel dental implants promoted bone regeneration around the nanotube Ti implants by upregulation of Runx-2, BMP-2/7, Osterix, and OPG in rat mandible model. MAP/Gel supports osseointegration of dental implant after implantation. It is hypothesized that MAP/Gel loaded into nanotube Ti dental implants may be applicable as a potential treatment for bone formation and proper integration of dental implants with alveolar bone. Graphical abstract.

Release pattern of dexamethasone after administration through an implant-mediated drug delivery device with an active plunger of super absorbent polymer

The implant-mediated drug delivery system (IMDDS) is a novel, innovative device that allows drug delivery through bone marrow. The purpose of this study was to investigate the effect of an active plunger component made of super absorbent polymer (SAP) on the plasma concentration of dexamethasone released from the IMDDS. The IMDDSs were installed in a total of 18 rabbits. After complete healing, dexamethasone was loaded with the SAP active plunger and with water to cause expansion in the test group (n = 9), while only the drug was loaded in the control group, as per the original protocol (n = 9). The release patterns of each group were monitored for 2 weeks by measuring the plasma concentration of the drug. Both groups showed sustained release of drug. However, the test groups showed more rapid increase in plasma concentration and higher area under the curve (AUC) throughout the observation period. The incorporation of a SAP active plunger component in the IMDDS resulted in an increase in initial release of drug and higher bioavailability within the observation period of 2 weeks after dexamethasone administration.